Barclays PLC Boosts Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Barclays PLC increased its holdings in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 409.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 59,778 shares of the company's stock after buying an additional 48,040 shares during the period. Barclays PLC owned 0.25% of UroGen Pharma worth $759,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock worth $103,000 after buying an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after purchasing an additional 5,890 shares during the period. Intech Investment Management LLC purchased a new position in shares of UroGen Pharma during the 3rd quarter valued at $155,000. Verition Fund Management LLC bought a new position in shares of UroGen Pharma in the third quarter worth $168,000. Finally, SG Americas Securities LLC purchased a new stake in shares of UroGen Pharma in the third quarter worth $179,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

URGN has been the subject of several research analyst reports. EF Hutton Acquisition Co. I raised UroGen Pharma to a "strong-buy" rating in a research note on Monday, October 14th. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a report on Friday, December 6th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of UroGen Pharma in a research note on Tuesday, October 15th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $43.70.

UroGen Pharma Stock Up 1.2 %

URGN stock traded up $0.13 during trading on Wednesday, hitting $10.65. 478,330 shares of the stock traded hands, compared to its average volume of 490,951. The stock has a market cap of $249.79 million, a price-to-earnings ratio of -3.38 and a beta of 1.06. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma Ltd. has a 1 year low of $10.26 and a 1 year high of $20.70. The firm's 50 day moving average is $11.77 and its two-hundred day moving average is $13.62.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same period in the previous year, the business posted ($0.68) EPS. On average, sell-side analysts anticipate that UroGen Pharma Ltd. will post -3.1 EPS for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.